🔗 Visit the ClinicalTrials.gov page for NCT01988077
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". | Toxins (Basel) | 2014 | 0.92 |
| 2 | Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells. | Front Oncol | 2014 | 0.85 |
| 3 | New developments in the management of advanced melanoma - role of pembrolizumab. | Onco Targets Ther | 2015 | 0.77 |